Published 2 days ago • loading... • Updated 1 day ago

Continuity Biosciences Awarded $9.6 Million Grant

Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. [...] The post Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention appeared first on Business News This Week.

6 Articles

연합뉴스-Yonhap News Agency

Lean Right

Continuity Biosciences Awarded $9.6 Million Grant

2 days ago·Seoul, Korea (the Republic of)

Read Full Article

tbbwmag.com

Gates Foundation Gives Bradenton Company $9.6 Million for HIV Research

The experimental implant could deliver HIV prevention medication for years after a single placement. The post Gates Foundation Gives Bradenton Company $9.6 Million for HIV Research appeared first on .

1 day ago

Read Full Article

The Queenslander

Reposted by

Business News This Week

Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention

BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company developing precision drug delivery platforms, today announced it has been awarded an up to $9.6 million grant from the Gates Foundation to advance a subcutaneous, ultra-long-acting antiretroviral (ARV) implant for HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries (LMICs).

2 days ago

Read Full Article

Kosmo Online

Continuity Biosciences Receives $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention

Funding supports development of subcutaneous implant designed to deliver HIV prevention drugs for several years through a single installation, advancing development toward IND application submission and initiation of first Phase 1 human studies BRADENTON, Florida and SEATTLE,...

2 days ago

Read Full Article